Ken Griffin Forte Biosciences, Inc. Call Options Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

Call Options

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q2 2024 Aug 14, 2024	BUY	$0.46 - $0.78 $966 - $1,638	2,100 Added 210.0%	3,100 $1,000
Q1 2024 May 15, 2024	SELL	$0.48 - $0.85 $5,136 - $9,095	-10,700 Reduced 91.45%	1,000 $0
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.82 $6,840 - $14,760	-18,000 Reduced 60.61%	11,700 $9,000
Q3 2023 Nov 14, 2023	BUY	$0.65 - $1.04 $7,930 - $12,688	12,200 Added 69.71%	29,700 $19,000
Q2 2023 Aug 14, 2023	SELL	$0.98 - $1.11 $1,372 - $1,554	-1,400 Reduced 7.41%	17,500 $18,000
Q1 2023 May 15, 2023	SELL	$0.98 - $1.06 $43,904 - $47,488	-44,800 Reduced 70.33%	18,900 $19,000
Q4 2022 Feb 14, 2023	BUY	$0.96 - $28.0 $17,280 - $504,000	18,000 Added 39.39%	63,700 $63,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.75 $8,798 - $230,325	-8,300 Reduced 15.37%	45,700 $49,000

Others Institutions Holding FBRX

# of Institutions

1

Shares Held

175K

Call Options Held

0

Put Options Held

0

Black Rock Inc. New York, NY

175K
Shares

$3.19 Million
0.0% of portfolio

About Forte Biosciences, Inc.

Ticker FBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,340,300
Market Cap $371M
Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

More about FBRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.